Metallothionein expression in epithelial ovarian cancer : effect of chemotherapy and prognostic significance

Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resista...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cancer research and clinical oncology 2000-12, Vol.126 (12), p.717-721
Hauptverfasser: WRIGLEY, E, VERSPAGET, H. W, JAYSON, G. C, MCGOWN, A. T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 721
container_issue 12
container_start_page 717
container_title Journal of cancer research and clinical oncology
container_volume 126
creator WRIGLEY, E
VERSPAGET, H. W
JAYSON, G. C
MCGOWN, A. T
description Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein.
doi_str_mv 10.1007/PL00008477
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72534118</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2586383731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-2fa8617bbc6d352843fc0c8210339c5dda436cb95b531f3bbd58e3790e02387d3</originalsourceid><addsrcrecordid>eNpdkU-LFDEQxYMo7uzqxQ8gQWEPQmsqlUwye5PFfzCiBz036XRlJ0tP0iY94n57s7uDC9alePCrR9Urxl6AeAtCmHfft6KVVcY8YitQKDtA1I_ZSoCBTktYn7DTWq9F09rIp-wEADSC0is2faXFTVNedjEnionTn7lQrU3xWzXHZUdTdBPPv12JLnHvkqfCLziFQH7hOXC_o31zoOLmG-7SyOeSr1KuS_S8xqsUQ7ybesaeBDdVen7sZ-znxw8_Lj9322-fvly-33Ye0S6dDM6uwQyDX4-opVUYvPBWgkDceD2OTuHaDxs9tCMCDsOoLaHZCBISrRnxjJ3f-7Y9fh2oLv0-Vk_T5BLlQ-2N1KgAbANf_Qde50NJbbd-I0Epre6gN_eQL7nWQqGfS9y7ctOD6G8f0D88oMEvj46HYU_jA3pMvAGvj4Cr3k2htGBi_cdZQKkB_wJumo0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>921445418</pqid></control><display><type>article</type><title>Metallothionein expression in epithelial ovarian cancer : effect of chemotherapy and prognostic significance</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>WRIGLEY, E ; VERSPAGET, H. W ; JAYSON, G. C ; MCGOWN, A. T</creator><creatorcontrib>WRIGLEY, E ; VERSPAGET, H. W ; JAYSON, G. C ; MCGOWN, A. T</creatorcontrib><description>Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/PL00008477</identifier><identifier>PMID: 11153145</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Carcinoma - drug therapy ; Carcinoma - metabolism ; Carcinoma - pathology ; Carcinoma - surgery ; Disease-Free Survival ; Female ; Female genital diseases ; Frozen Sections ; Gene Expression Regulation, Neoplastic - drug effects ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Metallothionein - biosynthesis ; Metallothionein - drug effects ; Middle Aged ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Platinum Compounds - therapeutic use ; Predictive Value of Tests ; Prognosis ; Radioimmunoassay ; Reoperation ; Risk Factors ; Survival Analysis ; Treatment Outcome ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2000-12, Vol.126 (12), p.717-721</ispartof><rights>2001 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c338t-2fa8617bbc6d352843fc0c8210339c5dda436cb95b531f3bbd58e3790e02387d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=813251$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11153145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WRIGLEY, E</creatorcontrib><creatorcontrib>VERSPAGET, H. W</creatorcontrib><creatorcontrib>JAYSON, G. C</creatorcontrib><creatorcontrib>MCGOWN, A. T</creatorcontrib><title>Metallothionein expression in epithelial ovarian cancer : effect of chemotherapy and prognostic significance</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - metabolism</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - surgery</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Frozen Sections</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Metallothionein - biosynthesis</subject><subject>Metallothionein - drug effects</subject><subject>Middle Aged</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Platinum Compounds - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Radioimmunoassay</subject><subject>Reoperation</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU-LFDEQxYMo7uzqxQ8gQWEPQmsqlUwye5PFfzCiBz036XRlJ0tP0iY94n57s7uDC9alePCrR9Urxl6AeAtCmHfft6KVVcY8YitQKDtA1I_ZSoCBTktYn7DTWq9F09rIp-wEADSC0is2faXFTVNedjEnionTn7lQrU3xWzXHZUdTdBPPv12JLnHvkqfCLziFQH7hOXC_o31zoOLmG-7SyOeSr1KuS_S8xqsUQ7ybesaeBDdVen7sZ-znxw8_Lj9322-fvly-33Ye0S6dDM6uwQyDX4-opVUYvPBWgkDceD2OTuHaDxs9tCMCDsOoLaHZCBISrRnxjJ3f-7Y9fh2oLv0-Vk_T5BLlQ-2N1KgAbANf_Qde50NJbbd-I0Epre6gN_eQL7nWQqGfS9y7ctOD6G8f0D88oMEvj46HYU_jA3pMvAGvj4Cr3k2htGBi_cdZQKkB_wJumo0c</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>WRIGLEY, E</creator><creator>VERSPAGET, H. W</creator><creator>JAYSON, G. C</creator><creator>MCGOWN, A. T</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20001201</creationdate><title>Metallothionein expression in epithelial ovarian cancer : effect of chemotherapy and prognostic significance</title><author>WRIGLEY, E ; VERSPAGET, H. W ; JAYSON, G. C ; MCGOWN, A. T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-2fa8617bbc6d352843fc0c8210339c5dda436cb95b531f3bbd58e3790e02387d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - metabolism</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - surgery</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Frozen Sections</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Metallothionein - biosynthesis</topic><topic>Metallothionein - drug effects</topic><topic>Middle Aged</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Platinum Compounds - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Radioimmunoassay</topic><topic>Reoperation</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WRIGLEY, E</creatorcontrib><creatorcontrib>VERSPAGET, H. W</creatorcontrib><creatorcontrib>JAYSON, G. C</creatorcontrib><creatorcontrib>MCGOWN, A. T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WRIGLEY, E</au><au>VERSPAGET, H. W</au><au>JAYSON, G. C</au><au>MCGOWN, A. T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metallothionein expression in epithelial ovarian cancer : effect of chemotherapy and prognostic significance</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>126</volume><issue>12</issue><spage>717</spage><epage>721</epage><pages>717-721</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>11153145</pmid><doi>10.1007/PL00008477</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0171-5216
ispartof Journal of cancer research and clinical oncology, 2000-12, Vol.126 (12), p.717-721
issn 0171-5216
1432-1335
language eng
recordid cdi_proquest_miscellaneous_72534118
source MEDLINE; SpringerNature Journals
subjects Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Biomarkers, Tumor - metabolism
Carcinoma - drug therapy
Carcinoma - metabolism
Carcinoma - pathology
Carcinoma - surgery
Disease-Free Survival
Female
Female genital diseases
Frozen Sections
Gene Expression Regulation, Neoplastic - drug effects
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Metallothionein - biosynthesis
Metallothionein - drug effects
Middle Aged
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Platinum Compounds - therapeutic use
Predictive Value of Tests
Prognosis
Radioimmunoassay
Reoperation
Risk Factors
Survival Analysis
Treatment Outcome
Tumors
title Metallothionein expression in epithelial ovarian cancer : effect of chemotherapy and prognostic significance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T15%3A47%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metallothionein%20expression%20in%20epithelial%20ovarian%20cancer%20:%20effect%20of%20chemotherapy%20and%20prognostic%20significance&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=WRIGLEY,%20E&rft.date=2000-12-01&rft.volume=126&rft.issue=12&rft.spage=717&rft.epage=721&rft.pages=717-721&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/PL00008477&rft_dat=%3Cproquest_cross%3E2586383731%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=921445418&rft_id=info:pmid/11153145&rfr_iscdi=true